To introduce a patient-reported erection fullness scale (% fullness) after robot-assisted radical prostatectomy (RARP) as a qualitative adjunct to the five-item version of the International Index of Erectile Function (IIEF-5) and as a 90-day predictor of 2-year potency outcomes.
Introduction
Erectile dysfunction (ED) is commonly encountered in the short and long term after radical prostatectomy (RP). ED has been reported to vary dramatically from 12% to 96%, depending on patient demographics, technique and surgeon skill and experience [1] [2] [3] [4] . While there is an established need to use validated questionnaires to assess preoperative sexual function, there is a lack of consensus regarding assessment of sexual function recovery after RP [5] [6] [7] [8] . This is particularly problematic in men with normal preoperative sexual function (five-item version of the International Index of Erectile Function [IIEF-5] score [22] [23] [24] [25] as it is of major consequence to their quality of life [9] . Although men with early recovery of potency (within 90 days) reliably maintain long-term potency, men with incomplete recovery have no reliable, early predictors of long-term potency recovery [6, 7] .
The IIEF-5 is the most utilized and validated questionnaire to assess potency in men who have undergone RP. At 90 days post-RP, 65-75% of men report scores of <15, which poorly discriminate partial return of erections or, more importantly, the ultimate likelihood of potency recovery [11] [12] [13] . Initially introduced as an adjunct to the IIEF-5, %fullness is a single-item questionnaire to qualitatively assess postoperative fullness of erections compared with baseline. Over time, we have recognized the potential of %fullness as a more complete description of partial erection recovery at 90 days and, therefore, expanded our experience to use 90-day %fullness as a metric for 2-year potency outcomes. The present study evaluates this novel 90-day %fullness scale as a means to predict 2-year potency recovery.
Methods
Data were prospectively collected and entered into an electronic database with institutional review board approval. All men with IIEF-5 scores of 22-25 undergoing robot-assisted radical prostatectomy (RARP) by a single surgeon (T.A.) between 2004 and 2014 were initially included. Peri-operatively, all patients were prescribed a daily dose of phosphodiesterase-5 inhibitors (tadalafil and sildenafil). All men who were receiving erectile dysfunction therapies, including penile rehabilitation and/or ED medications beyond the daily dose of phosphodiesterase-5 inhibitors, were excluded from the study.
For the purposes of the present study, erectile function was assessed using the following self-administered assessment tools: (1) two components of erections sufficient for intercourse (ESI): 'Are your erections firm enough for penetration?' and 'Are they satisfactory?'; (2) the IIEF-5 questionnaire; and (3) %fullness of erections: 'Please indicate the fullness you are able to achieve in your erections at this time, compared to before surgery: 0-100%'.
Because the present study was an exploration of percentage of erection fullness as a means to predict partial erection recovery, men with complete follow-up at 3, 9, 15 and 24 months were included (n = 299). Table 1 shows the demographics for the 299 men who had complete follow-up at all time points (3, 9, 15 and 24 months). Table 2 shows the final potency model at 24 months, after the following logistic regression models were generated: (1) preoperative characteristics; (2) %fullness tertile at 3 months, after adjusting for significant preoperative characteristics; and (3) 3-month IIEF-5 scores, after adjusting for significant preoperative characteristics (data not shown). Variables included in the stepwise regression were those that were significantly associated with potency at 24 months in univariate analysis. Significant variables were included in an overall multivariate logistic regression model using forward and backward stepwise regression.
Receiver-operating characteristic curves were generated to compare sensitivity and specificity of 3-month %fullness and IIEF-5 in predicting 24-month recovery of ESI. A subsequent analysis was performed to assess the general applicability to all patients reporting 3-month %fullness and potency outcomes variably at 9, 15 and 24 months. A two-tailed, Student's t-test was used to evaluate the similarity between patients with complete responses (n = 299) and the full patient cohort (N = 540).
Results
Men with complete follow-up (n = 299) were stratified into three %fullness tertiles: 0-24%, 25-74% and 75-100%, which included 90 (30.1%), 97 (32.4%), and 112 men (37.5%), respectively. A total of 216 men (72.2%) regained potency, which was defined as an affirmative answer to both ESI questions. Table 1 shows significant differences between potent vs non-potent groups with respect to age, IIEF-5 score, PSA, pathological stage, seminal vesicle invasion and nervesparing status. Table 2 shows the final logistic regression of peri-operative variables (up to 3 months post-surgery) contributing to potency at 24 months. When considering only 3-month IIEF-5, the predictive capability (adjusted R 2 ) was 0.294. By contrast, 3-month %fullness had an adjusted R 2 of 0.378 (P < 0.001, data not shown). After adjustment for age, nerve-sparing status had a mild effect compared with % fullness tertile (odds ratio 5.09 for 25-75% and 116 for >75%). Figure 1 shows the predictability of 3-month %fullness tertile for men with complete responses at all follow-up time points (n = 299). Although men who reported 0-24% fullness at 3 months showed poor recovery (19%) throughout the first 15 months postoperatively, 30% ultimately regained potency by 24 months. Further, those reporting 25-74% fullness at 3 months had low rates of potency recovery (72%) up to The receiver-operating characteristic curves showing the sensitivity and specificity analysis of 90-day %fullness and IIEF-5 score in predicting 24-month recovery of ESI are shown in Fig. 2 . If specificity is optimized to 98.5%, both the IIEF-5 and %fullness scales have similar sensitivity (at an IIEF-5 score threshold of 13 and a 75% fullness threshold, respectively). If sensitivity is optimized to 82%, %fullness has 70.1% specificity, as compared with specificity of the IIEF-5 of 44.6%. In this regard, %fullness can be used as a discriminator of men with inadequate partial erection recovery vs men who are at risk of long-term impotency. Figure 3 shows the use of %fullness as both an independent predictor and as an adjunct to the IIEF-5. When men (preoperative IIEF-5 score 22-25) were assessed at 90 days after RARP, 181/299 men (61%) had erections inadequate for intercourse. If an IIEF-5 score of 1-6 was used, 142/181 (78%) would be targeted for early intervention. By contrast, if 0-24% fullness is used, 88/181 men (49%) are targeted. If both the IIEF-5 and %fullness are used, this is reduced to 77/181 men (43%).
Recognizing the difficulty of attaining complete follow-up at all time points, however, we compared results of the full cohort with those who had complete follow-up data. Table S1 and Fig. 1 show the characteristic of men with responses to 3-month %fullness and variable follow-up throughout the 24-month period (n = 540). This overall patient group was comparable with the study group with complete responses and had very similar results in their potency recovery curves (Table S2) .
Discussion
Unlike most cancer surgery, where survival is the essential goal, RP (robot-assisted or open) is characterized as much by functional preservation of continence and sexual function as cancer control [9, 11] . Potency recovery is frequently defined by IIEF-5 scores or by ESI [12, 13] A systematic review by Ficarra et al. [12] previously noted ESI as the most commonly used definition of potency recovery. Some have recommended defining potency using various categorical IIEF-5 scores ≥15, ≥17 and ≥22 or at least a score of 3 (approximately half the time) on component 5 ('When you attempted intercourse, how often was it satisfactory to you?') [13, 14] . Consistent with our previous reports, men reporting affirmative ESI had an average IIEF-5 score of 21.4, and all of these men scored 3-5 on component 5 of the IIEF-5, and 63% of the men reported an IIEF-5 score of 22-25 [13] . Although specific definitions of potency recovery have yet to be definitively settled, all of the above-mentioned methods yield reasonably consistent, quantitative assessment [15] [16] [17] ; however, improvement in the quality of erections is not as easily discerned.
In an effort to add a qualitative component to assess partial recovery of erections and evaluate erection quality, we supplemented our standard follow-up ESI and IIEF-5 questionnaires with an erection fullness question. As a single adjunctive question, %fullness is precise, simple to understand, easy to answer, independent from penetration, and yields the highest patient response rates [10] . Postoperatively, we noted that men reporting IIEF-5 scores of 15-21 typically had a %fullness score of 75-85% and, logically, men with IIEF-5 scores of 22-25 generally had % fullness of 95-100%. It was not unusual, however, to see an affirmative ESI, but an IIEF-5 score of 8-10, particularly for 
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© 2018 The Authors BJU International © 2018 BJU International men without sexual partners. Often, these men only answer components 1 and 2 of the IIEF-5 and indicate no sexual activity for the remaining questions. While a low %fullness supports a lack of potency consistent with the low IIEF-5 score, a high %fullness probably indicates a potent man without a partner.
Notwithstanding, the most important finding of the present study is the ability of %fullness to provide an early, 90-day metric for long-term potency recovery, either as an independent predictor or as a qualitative adjunct to the IIEF-5. While IIEF-5 score and ESI are most useful in assigning a dichotomous potency, their predictive value for subsequent recovery has not been reported. When men with normal preoperative sexual function (IIEF-5 scores 22-25) are assessed at 90 days after RARP, 39% report ESI and the remaining 61% are not accurately stratified with the IIEF-5. We suggest the use of %fullness to identify those with a high likelihood of long-term impotence; 54% will report 0-24% fullness, of whom 72% will not recover potency. This is not only statistically significant, but is also clinically relevant such that the use of 90-day %fullness allows the identification of patients who can be counselled for secondary intervention.
Mulhall et al. [18] and Goldstein et al. [19] have shown that sexual function closely correlates with erection hardness. As a single-item questionnaire, 90-day %fullness represents a capable predictor of long-term ED, with a notably higher sensitivity and specificity when compared with the IIEF-5. As a continuous measure of penile rigidity, the erection fullness scale is useful for several reasons. The ability of the %fullness scale to discriminate between impotent men and men with intermediate recovery of sexual function allows physicians to identify patients who are most likely to benefit from early, therapeutic interventions, such as injection therapy.
To this effect, the recovery of potency, or more accurately, cavernosal nerve function, seen in the present study, also illustrates Seddon's description of the three classes of nerve injury and recovery: neurapraxia, axonotmesis and neurotmesis [20] . Neurapraxia consists of a mild, concussion-like injury attributable to blunt impact or stretch injury to the perineural sheath without axonal structural damage. The recovery process is weeks to a few months, which is consistent with the recovery curve for patients who report 75-100% fullness at 3 months. For patients with axonotmesis (grade 2 injury), injury to the axon has occurred and, as long as the nerve sheath is intact, the nerve(s) will undergo Wallerian degeneration and then regeneration from the point of injury to the end organ. In this scenario, regrowth of the axon advances~1 mm per day (or 2.54 cm per month), extending the recovery period to 6-24 months, as shown by the steady increase of potency in the 25-74% fullness quartile at 9-24 months' follow-up [21] . Lastly, for the lowest tertile (0-24%), these patients have a blend of axonotmesis but mostly neurotmesis; some may recover, but the majority do not. As the most severe injury resulting from significant injury to the axon and myelin sheath, patients with neurotmetic injury experience the highest probability of neuronal death and, therefore, have little capacity for axonal regrowth [21, 22] . The correlation between recovery from these peripheral nerve injuries and the results of the %fullness predictive model further legitimize quantitating fullness of erections to estimate recovery of potency and identifies patients at high risk of impotency post-RARP.
Although data were prospectively collected, there are limitations inherent to the retrospective nature of the study. We conducted the present analysis first on men with IIEF-5 scores between 22 and 25 with complete responses at 3, 9, 15 and 24 months to fully track partial recovery of erections. To model 2-year potency with incomplete follow-up, we have also included a supplementary analysis of all patients reporting 90-day %fullness and 24-month ESI, with similar predictive capability. Inclusion criteria of only men with normal baseline sexual function is consistent with our effort to demonstrate proof-of-concept, but the findings are only applicable to men with preoperative IIEF-5 scores between 22 and 25. Further, potency recovery was defined as two affirmative answers to the ESI questionnaire. To assess consistency between the ESI and IIEF-5, we performed a similar analysis with potency defined as IIEF-5 scores ≥15, and the findings were similar (data not shown).
The present results are hypothesis-generating. In experience gained at our centre, these results are consistent despite changes in surgical technique and patient characteristics.
While general applicability and predictability across other surgeons is limited, validation studies are currently underway.
In conclusion, the present study describes the preliminary results for a simple, single-item, and intuitive patient-reported scale of erection fullness after RARP. In addition to its adjunctive and qualitative contribution to the IIEF-5 at any time point, it also appears to merit consideration as a means to identify patients for counselling at 90 days post-RARP. A %fullness of 0-24% at 3 months was a strong predictor in that~70% of this group would experience long-term failure to recover potency; thus, we suggest two functions of the % fullness scale in modelling long-term sexual function recovery: as an adjunct to the IIEF-5 and ESI questionnaires or as a single-item question to predict impotent men who would be most likely to benefit from therapeutic interventions.
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